Tissue Proteomic Assay Development
and Discovery Programs
Using our proprietary tissue analysis platform we are developing
new targeted tissue assays focusing on cancer. Our Liquid Tissue® MRM technology is providing the foundation for new ways to accurately measure proteins in standard formalin-fixed paraffin
embedded tissue. The assays will provide information to guide
treatment decisions; the presence of protein drug targets, or
which
biological pathways are activated in tumors to aid prognosis
and drug selection.
Liquid Tissue® MRM assays can be multiplexed so it is, for
example, possible to measure several
different targets, or a number of proteins in a pathway simultaneously.
We also engage in biomarker discovery projects where our
technology is used for global proteomic profiling. Comparing
tissue samples from e.g. responders and responders can help
identify differentially
expressing candidate biomarkers, which can subsequently be
measured using MRM based methods.
Projects
and Collaborations
Contact
us to discuss how we can work together in areas that
complement your own internal needs,
resources and expertise.
Liquid Tissue technology is protected by U.S. Patent 7,473,532
and patents pending and foreign equivalents thereof.
DIRECTOR technology is protected by U.S. Patents 7,294,367
and 7,381,440 and foreign equivalents thereof.
Expression Pathology Inc. is a leader in tissue proteomics.
Our scientists have extensive experience in tissue proteomic assay development, pathology,
proteomics and tissue analysis. Call us to discuss
opportunities for collaborative assay development.
The Liquid Tissue® MS protocol prepares FFPE samples
for mass spec analysis. Complete solubilization captures the entire protein
content. Mass spec friendly. Requires only 30,000 cells for multiple
mass spectrometry analyses.
The Director® Laser Microdissection Slides
provide the fastest, easiest and most accurate way
to collect specific cellular features from tissue
sections. Engineered for use with current
Leica LMD, PALM Zeiss and MMI laser microdissection
system.
news sidebar
News & Events
Expression Pathology Collaborates with Toronto’s Sick Kids Hospital and University Health Network on New Mass Spec EGFR Test, May 4, 2010, (press release)
Thermo
Fisher announced a collaboration with Expression Pathology to develop
Liquid Tissue MRM Assays of Cancer Proteins In Microdissected FFPE Tissue,
December 16, 2009 (press
release)
The Mayo
Clinic has licensed non-exclusive rights to the Liquid Tissue(R) patent
for use in diagnosis of systemic amyloidosis in FFPE tissue, November 17, 2009 (press
release)
Expression
Pathology raises $6.5 Million
to develop personalized medicine assays for protein biomarkers in FFPE
Tissue. April 20, 2009 (press
release)
